drugset / Trial / NCT05695521

Regulatory T Cells for Amyotrophic Lateral Sclerosis

NCT05695521 ↗

Phase 1 Active not recruiting 66 enrolled Cellenkos, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.

Timeline

Start
2023-04-03
Primary completion
2026-05
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CK0803 Cell therapy 100 cells Intravenous